Related Experiment Video
Updated: Mar 30, 2026
05:58
Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
Published on: October 13, 2023
1.8K
Microfluidic devices to enrich and isolate circulating tumor cells.
1Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois, 833 S. Wood St., Chicago, IL 60612, USA. sphong@uic.edu.
Lab on a Chip
|November 10, 2015
Summary
Microfluidic devices offer promising advantages for detecting circulating tumor cells (CTCs) as cancer biomarkers. These advanced systems enable precise, automated analysis with reduced sample and reagent use, paving the way for clinical impact.
Area of Science:
- Biomedical Engineering
- Oncology
- Analytical Chemistry
Background:
- Circulating tumor cells (CTCs) are vital biomarkers for cancer diagnosis and prognosis.
- Conventional CTC detection methods face limitations in sensitivity, specificity, and throughput.
- Microfluidic devices present a novel platform for advanced CTC analysis.
Purpose of the Study:
- To review the advantages and potential of microfluidic devices for CTC detection.
- To categorize advancements in microfluidic CTC detection based on key technological features.
- To identify challenges hindering the clinical translation of microfluidic CTC detection technologies.
Main Methods:
- Comprehensive literature review of microfluidic devices for CTC detection.
- Categorization of devices by miniaturization, nanotechnology integration, and analysis capabilities (in situ/sequential).
- Analysis of advantages, including low sample/reagent consumption, flexibility, and automation.
Main Results:
- Microfluidic devices offer significant advantages over conventional systems, including precision, automation, and reduced resource requirements.
- Key advancements include miniaturized analytical systems, integration with nanotechnologies, and capabilities for in situ or sequential CTC analysis.
- The review highlights diverse microfluidic approaches tailored for sensitive and specific CTC capture and characterization.
Conclusions:
- Microfluidic devices hold substantial promise for improving CTC detection, offering a scalable and efficient platform.
- Further development and validation are necessary to overcome current challenges and achieve widespread clinical impact.
- These technologies are poised to revolutionize cancer diagnostics and prognostics through enhanced biomarker analysis.
